CSI Market
Sign In | Register

Arcadia Biosciences Inc (RKDA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RKDA Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Arcadia Biosciences Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-10.65
Depreciation & amortization0.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.28
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation0.03
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Derivative Liabilities Related To Convertible Promissory Notes-
Investment Income Amortization Of Premium-
Payment Of Research And Develop Fees With Cost Investment-
Initial Loss On Common Stock Warrant And Common Stock Adjustment Feature Liabilities-
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Contract With Customer Liability-
Gain On Extinguishment Of Warrant Liability-
Loss On Extinguishment Of Warrant Liability-
Noninterest Expense Offering Cost0.42
Corporate Securities Received In Exchange For License Agreement-
Marketable Securities Realized Gain Loss-
Operating Lease Right Of Use Asset Amortization Expense-
Change In Fair Value Of Common Stock Warrant And Option Liabilities-1.19
Issuance And Offering Costs Allocated To Liability Classified Options-
Gain Loss On Private Placement-
Disposal Group Including Discontinued Operation Impairment Of Property And Equipment-
Impairment Of Right Of Use Asset-
Increase Decrease In Operating Lease Liability-
Increase Decrease In Operating Lease Payments-
Income taxes0.00
Unrealized Gain (Loss) on Investments-4.30
Increase (Decrease) in Accounts Receivable0.13
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.08
Other Working Capital-0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities13.74
Discontinued operations0.00
Net Cash flow from Operating Activities-1.42
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Cost Method Investments-
Payment For Sale Of Disposal Group Including Discontinued Operation-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net5.34
Proceeds From Issuance Of Redeemable Convertible Preferred Stock And Common Stock Warrants Net Of Issuance Costs-
Payments On Notes Payable To Related Party-
Payments For Notes Payable And Convertible Promissory Notes-
Payments For Capital Lease Obligation-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Common Stock And Warrants From Purchase Agreement-
Proceeds From Issuance Of Common Stock And Warrants From Offering-
Payments Of Offering Costs-0.29
Payment On Notes Payable-
Warrant Issued Included In Offering Costs-
Payments Of Deferred Offering Costs-
Payments Of Transaction Costs Relating To Extinguishment Of Warrant Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.34
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.42
Total Cash Flow3.92
4 historic quarters locked

Sign in to unlock the full Arcadia Biosciences Inc cash flow history.

Sign In Create Free Account

About Arcadia Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-349205

Figures are derived from filed reports and may be restated. Historical data is subject to revision.